Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Q2 2023 · 10-Q
Revenue$2.09M$2.09M−16.6% vs Q2 2022 Net Income-$11.11M-$11.11MN/M vs Q2 2022 EPS Diluted-$0.40-$0.40no prior Q2 2022 on file Gross Profit$248,000−73.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
Operating Cash Flowderived-$8,072,000— Free Cash Flowderived-$8,627,000— Margins · derivedGross margin11.9%−25.1 pt vs Q2 2022
Operating margin-467.1%−383.1 pt vs Q2 2022
Net margin-531.9%−448.9 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 11, 2023 · 42 d after period end